The Boon of Liquid Biopsies in Genomic Cancer Care
June 2017 - Vol. 6 No. 5 - Page #6

Q&A with Pravin J. Mishra, PhD
Director, Research and Development Center
Intermountain Precision Genomics
Intermountain Healthcare

MedicalLab Management: What are your laboratory’s therapeutic initiatives and goals, including the use of next generation sequencing?
Pravin Mishra: Intermountain Healthcare is internationally recognized as a highly regarded health care system, and in perpetuating this reputation, Intermountain initiated a precision medicine program to provide our patients with individualized cancer treatment. In order to deliver novel insights into the biology of disease, identify de novo targets, and benefit patients, our laboratory is motivated to interrogate new methodologies and technologies incorporating a bench-to-bedside approach (ie, research to clinic).

To read the full article, please log in or register.

Current Issue

Our mission is to provide health system professionals with information to streamline operations and promote patient safety.

As a requester to MLM you will receive all monthly issues, as well as our annual Resource Guide of product and service providers and all of our timely supplements on hot-button issues.

Thank you for reading MLM, and we look forward to providing you with information to enhance the field.